7 completed. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 1 | Completed 1 |
Follow fosamprenavir: new trials by email Literature Review of fosamprenavir trials Research Report on fosamprenavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Interaction Study to Assess Drug Levels in Healthy Adult Subjects Maraviroc, Fosamprenavir, Ritonavir - Healthy | Phase 2 | Completed | Garden State Infectious Disease Associates, PA | 45 | 2008-10-01 | 2016-01-29 |
| Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections | Phase 2 / Phase 3 | Completed | University of California, San Diego | 59 | 2007-03-01 | 2014-04-23 |
| Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127) Fosamprenavir, Saquinavir - HIV Infections | Phase 2 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 61 | 2005-12-01 | 2026-04-02 |
| 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection LEXIVA (GW433908), Ritonavir - Infection, Human Immunodeficiency Virus I | Phase 2 | Completed | ViiV Healthcare | 110 | 2004-07-01 | 2017-03-07 |
| Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects GW433908, ritonavir - Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | Completed | ViiV Healthcare | 59 | 2003-10-23 | 2023-10-10 |
| A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years ritonavir, fosamprenavir - HIV Infection | Phase 2 | Completed | ViiV Healthcare | 69 | 2002-07-01 | 2017-03-03 |
| Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV lopinavir/ritonavir, indinavir sulfate, tenofovir disoproxil fumarate - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 53 | 2021-11-01 |
HIV Infections (6) · Infections (2) · AIDS Dementia Complex (1) · Acquired Immunodeficiency Syndrome (1) · Cognitive Dysfunction (1)
ViiV Healthcare (3) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Garden State Infectious Disease Associates, PA (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of California, San Diego (1)
United States (6) · Canada (2) · Portugal (2) · Puerto Rico (2) · Romania (2) · Russia (2) · South Africa (2) · Spain (2) · Argentina (1) · Belgium (1) · France (1) · Italy (1) · Mexico (1) · Netherlands (1)
David V Condoluci, DO (1) · Douglas Richman, MD (1) · Jean Pierre Aboulker, MD (1) · Joseph J. Eron, MD (1) · Roland Landman, MD (1) · Ronald J Ellis, MD, PhD (1)
PMID 19420019, PMID 23811744, PMID 24352352
2005 (1), R01MH058076 (1)